<DOC>
	<DOCNO>NCT02405533</DOCNO>
	<brief_summary>This phase II randomize , double-blind placebo-controlled , crossover trial . The primary outcome trial achieve durable eradication persistent high risk HPV infection determine HPV negative test result achieve active treatment AHCC maintain 6 month post supplementation 12 month post completion AHCC treatment compare placebo .</brief_summary>
	<brief_title>Phase II Evaluation AHCC Eradication HPV Infections</brief_title>
	<detailed_description>This phase II randomize , double-blind placebo-controlled , crossover trial . The primary outcome trial achieve durable eradication HPV infection determine HPV negative test result achieve active treatment AHCC maintain 6 month post supplementation 12 month post completion AHCC treatment Group 1 . We follow patient least 12 month 30 month depend success achieve negative HPV test result . After receive AHCC 3 gram x 6 month positive end 12 month study treatment , consider treatment failure . If negative completion 6 month AHCC supplementation + 6 month placebo , continue study another six month ( 2 visit ) confirm remain HPV negative durable response . Group 2 serve untreated control time point ( end supplementation , 6 , 9 , 12 month post end AHCC supplementation .</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<criteria>• Women 30 year age HPV positive test normal/negative cytology , atypical cell , ASCUS , CIN1 CIN2 cervical dysplasia within three month study entry . Women must 2 HPV positive test normal/negative cytology , atypical cell , ASCUS , CIN1 CIN2 cervical dysplasia 1 great 6 month 18 month prior study entry 1 great 24 month prior study entry . Women child bear potential must negative urine pregnancy test within 7 day therapy start . Patients must adequate hematologic , renal , hepatic function note lab within previous 12 month : ANC &gt; /= 1,500 cells/mm3 , platelets 100,000 &gt; /= cells/mm3 ; Creatinine clearance &gt; /= 60 mL/min ( estimate Cockcroft Gault equation ) , total bilirubin , SGPT , SGOT , alkaline phosphatase &lt; /= 1.5 time normal . Patients childbearing age must agree use effective method contraception ( oral contraceptive , condom , etc . ) study . • History myocardial infarction within past 6 month , unstable angina , CHF , uncontrolled hypertension ( &gt; 140/90 ) . Women current prior diagnosis cancer Women current diagnosis CIN3 cervical dysplasia Women pregnant breast feeding . Women history Hepatitis ( autoimmune , A , B , C ) antigen positive Patients history significant psychiatric disorder ( schizophrenia , bipolar , psychosis ) uncontrolled seizure . Patients significant medical comorbidities discretion primary Gynecologist . Including immunosuppressive condition ( i.e . HIV+ , rheumatoid arthritis , etc ) take immune modulation mediation ( i.e . immunosuppressant ) Women take AHCC within past six month . Women currently take immune modulate nutritional supplement . Patients undergone hysterectomy ( supracervical hysterectomy allow )</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AHCC</keyword>
	<keyword>nutritional supplement</keyword>
	<keyword>HPV</keyword>
</DOC>